ICG used as a tracer for sentinel lymph nodetechnetium 99 used as a tracer for sentinel lymph node
ICG used as a tracer for sentinel lymph node: ICG used as a tracer for sentinel lymph node instead of technetium 99
technetium 99 used as a tracer for sentinel lymph node: technetium 99 used as a tracer for sentinel lymph node instead of ICG
Study summary
This single-institution pilot study uses a pre- and post-implementation design to evaluate the implementation of ICG fluorescent imaging for sentinel lymph node biopsy (SLNB) in an Italian hospital.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Clinically node-negative, DCIS or invasive stage T1-T3 breast cancer confirmed by biopsy
* Preoperative axillary ultrasound to confirm clinical node-negative status
* Indication for breast cancer surgery with SLNB via axillar incision
* Written informed consent according to national regulations
Exclusion Criteria:
* Patients \< 18 years old.
* Indication for breast cancer surgery with SLNB via mastectomy incision
* Known allergy for ICG, intravenous contrast or iodine
* History of axillary lymph node dissection
* Pregnancy or breast-feeding
* Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol
Primary outcome measure(s)
Identification rate of SLNs achieved by 99mTc-nanocolloid or the fluorescent signal of ICG — through study completion, an average of 1 year measure the percentage of sentinel lymph nodes identified by the 99mTc nanocolloid or the ICG fluorescent signal (%)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
